GlassScriptPhysician profile
Marc D Grobman
NPI 1063484442
$13,105.29
in general payments reported to CMS, 2019-2025
55 companies · $1,982 in 2025
The $1,982 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,136 · 2020: $1,476 · 2021: $1,741 · 2022: $1,809 · 2023: $2,124 · 2024: $1,838 · 2025: $1,982.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,913 · Education: $30.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,912.93 |
| Education | $30.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,565.07 | 2020-2025 | |
| Glaxosmithkline, LLC. | $1,491.75 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $1,298.51 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $1,133.53 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $1,000.88 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $765.46 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $668.14 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $433.32 | 2019-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $414.98 | 2019-2023 | |
| Bausch Health US, LLC | $399.43 | 2019-2025 | Aplenzin, Wellbutrin |
| Esperion Therapeutics, INC. | $373.72 | 2021-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $369.00 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $345.24 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $322.18 | 2019-2025 | Xifaxan |
| Astellas Pharma US INC | $302.39 | 2019-2025 | Veozah, Myrbetriq |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Grobman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.